BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 3134662)

  • 21. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
    Bouffioux C
    Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
    [No Abstract]   [Full Text] [Related]  

  • 22. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract]   [Full Text] [Related]  

  • 23. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of superficial carcinoma of the bladder.
    Paulson DF
    Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
    [No Abstract]   [Full Text] [Related]  

  • 25. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 29. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Soloway MS
    Prog Clin Biol Res; 1990; 350():71-9. PubMed ID: 2117289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of intravesical therapy for superficial bladder cancer.
    Lamm DL
    Urol Clin North Am; 1992 Aug; 19(3):573-80. PubMed ID: 1636241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intravesical BCG vaccine in bladder cancer].
    Beisland HO; Sander S
    Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
    Mori K; Lamm DL; Crawford ED
    Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.